



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,846	06/06/2002	John Carter	3920-0110P	5250

2292 7590 04/01/2004

BIRCH STEWART KOLASCH & BIRCH  
PO BOX 747  
FALLS CHURCH, VA 22040-0747

EXAMINER

CHOI, FRANK I

ART UNIT	PAPER NUMBER
----------	--------------

1616

DATE MAILED: 04/01/2004

13

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/089,846

Applicant(s)

CARTER, JOHN

Examiner

Frank I Choi

Art Unit

1616

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 29 October 2003.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1 and 21-56 is/are pending in the application.
- 4a) Of the above claim(s) 27 and 35 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 21-26, 28-34, 36-56 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1 and 21-56 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some    \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>3</u> . | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Election/Restrictions***

Applicant's election without traverse of copper orotate, manganese orotate, iron orotate, zinc orotate, sodium salicylate, sublimed sulfur and proline in Paper No. 9 is acknowledged. Claims 1, 21-26, 28-34, 36-56 read on the elected species. Although Applicant indicated that claims 37-45 do not read on the elected species, the claims do claim in the alternative an equivalent amount of active ingredient if other than metal gluconates are used. As such, claims 37-45 will also be prosecuted to the extent that they read on the elected species. New claims 54-56 appear to read on the elected species. Claims 27, 35 are withdrawn from prosecution as directed to non-elected species.

### ***Specification***

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

### **Arrangement of the Specification**

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or  
REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.)
- (e) BACKGROUND OF THE INVENTION.

Art Unit: 1616

- (1) Field of the Invention.
- (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) BRIEF SUMMARY OF THE INVENTION.
- (g) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (h) DETAILED DESCRIPTION OF THE INVENTION.
- (i) CLAIM OR CLAIMS (commencing on a separate sheet).
- (j) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (k) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

The Specification must include a section entitled "Brief Description of the Drawings".

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 50,51 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treatment of neoplastic disease, does not reasonably provide enablement for prevention of neoplastic disease. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

*The nature of the invention:*

The invention is directed to a method of treating or preventing neoplastic disease in a human or animal patient with a physiologically acceptable source of assimilable copper other than a copper salicylate complex; salicylic acid or an alkali or alkaline earth metal salt thereof; and vitamin C, with the dependent claim further comprising a physiologically acceptable source of assimilable manganese.

Art Unit: 1616

*The state of the prior art and the predictability or lack thereof in the art:*

The prior art appears to show treatment of neoplastic diseases but not prevention of neoplastic diseases, as such, predictability in the art appears to be low.

*The amount of direction or guidance present and the presence or absence of working examples:*

The specification discloses pharmaceutical formulations and use in the treatment of various neoplastic diseases, however, the Specification does not appear to show prevention of neoplastic diseases.

*The breadth of the claims and the quantity of experimentation needed:*

The claims are broad in that they claim prevention of neoplastic diseases, with any physiologically source of copper except copper salicylate; salicylic acid or alkali or alkaline earth metal salt thereof and vitamin C; or further comprising any physiologically source of manganese. As such, in light of the above, one of ordinary skill in the art would be required to do undue experimentation in order to show that the composition prevents any given neoplastic disease.

***Claim Rejections - 35 USC § 102/103***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1616

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 21-26, 28-34, 36, 46-56 rejected under 35 U.S.C. 103(a) as being unpatentable over Jackson et al. (US Pat. 5,654,011) in view of Riley et al. (US Pat. 5,948,443, Wawretschek et al. (US Pat. 4,061,741), Verde (US Pat. 4, 985,257) and Bounous et al. (US Pat. 5,290,571).

Jackson et al. disclose compositions and methods for providing dietary supplements to meet the needs of pre-perimenopausal women, including pregnant women, and to reduce the risk of cancer comprising copper, manganese, zinc, iron and vitamin C (Column 2, lines 25-51, Column 4, lines 13-23, Column 8, lines 30-68).

Riley et al. discloses a composition and method of reducing the risk of cancer by providing dietary supplements to women which comprise aspirin or bioequivalent forms, such as salicylic acid or other salicylates, iron, zinc, manganese, copper and Vitamin C (Column 9, lines 30-55, Column 21, lines 7-63, Table III).

Wawretschek et al. disclose that the analgesic efficiency of sodium salicylate can be reinforced by combining with a salt of orotic acid (Claims 10, 30, 39).

Verde discloses that hemorrhoids are associated with increased pressure in the portal venous system such as during pregnancy and a method of treating the same with sublimed sulfur (Column 2, lines 18-32, lines 65-68).

Bounous et al. disclose a composition containing proline to which is added vitamin C, iron, zinc, copper which is used to treat cancer (Column 6, lines 10-31, Table 1, Column 7, Column 24, lines 25-68, Table 10).

The difference between the prior art and the claimed invention is that the prior art does not expressly disclose the use of copper orotate, manganese orotate, iron orotate, sodium salicylate, sublimed sulfur, proline and vitamin C. However, the prior art amply suggests the same as the prior art discloses dietary supplements which combine various nutrients, such as copper, manganese, vitamin C with salicylates for use in women and reducing the risk of cancer, the combination of sodium salicylate and salts of orotate to increase the efficacy of the sodium salicylate, the use of copper, manganese, iron and vitamin C for use in pregnant women and reducing the risk of cancer, sublimed sulfur for treatment of hemorrhoids which occurs in pregnant women and proline which can be combined with other nutrients, such as copper, iron, zinc and vitamin C and is used to treat cancer. As such, it would have been well within the skill of one of ordinary skill in the art would have been motivated to modify the prior art by providing the copper, iron, zinc and manganese as salts of orotate so as to increase the efficacy of the sodium salicylate and to combine copper, iron, zinc and manganese with sodium salicylate and vitamin C with the expectation that the composition would be suitable for use in pregnant women and for treatment of cancer, to further add proline with the expectation that the same would be suitable for treatment of cancer and to add sublimed sulfur as pregnant women are known to suffer from hemorrhoids.

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Art Unit: 1616

***Conclusion***

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier number for accessing the facsimile machine is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (571)272-0610. Examiner maintains a flexible schedule. However, Examiner may generally be reached Monday-Friday, 8:00 am – 5:30 pm (EST), except the first Friday of the each biweek which is Examiner's normally scheduled day off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. Thurman Page, can be reached at (571)272-0602. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (571) 272-1600.

FIC

March 27, 2004



**S. MARK CLARDY  
PATENT EXAMINER  
GROUP 1200**  
1616